Form 8.3

Summary by AI BETAClose X

Qube Research & Technologies disclosed on 12-11-2026 an opening position in Bodycote plc held as at 11-11-2026 consisting of 5,555,332 cash-settled derivatives representing 3.26% of the 17 3/11p ordinary share class, with no direct holdings or short positions (0.00%) and no subscription rights; recent equity-swap trades show a net increase of 3,524 swaps across prices 917.00–918.00 GBp per share, implying approximately £50.9m of economic exposure at those levels; no indemnities, voting arrangements or stock-settled derivatives were disclosed.

Disclaimer*

Companies

Bodycote (BOY)
UK 100

Latest directors dealings